Protara Therapeutics Q1 2022 net loss narrows to $10.8M; cash $118.5M funds into mid-2024

Protara Therapeutics, Inc.

2023-Q1 EPS reported -$0.96

Net loss of $10.8M ($0.96/share) versus $13.5M ($1.20/share) in Q1 2021.
Cash and equivalents $118.5M as of March 31, 2022; expected to fund operations into mid-2024.
Phase 1 ADVANCED-1 trial of TARA-002 for NMIBC first patient dosed in March 2022.
FDA preliminary guidance received for TARA-002 in lymphatic malformations; Phase 2 trial planning underway.
U.S. patent issued for IV Choline Chloride composition with term expiring in 2041.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.